Danish pharmaceutical company Novo Nordisk (NVO.US) announced on Friday the closure of its cell therapy department, which was responsible for drug development for Type 1 diabetes.
The company stated in a statement that it is seeking partners to continue advancing related research. According to reports from Borsen, nearly all of the approximately 250 employees in that department were laid off, and Novo Nordisk did not disclose further specific details

Danish pharmaceutical company Novo Nordisk announced on Friday the closure of its cell therapy department, which is responsible for drug development for Type 1 diabetes. The company stated in a statement that it is seeking partners to continue advancing related research. According to reports from《Borsen》, nearly all of the approximately 250 employees in that department were laid off, and Novo Nordisk did not disclose further specific details

諾和諾德全面裁撤糖尿病細胞療法部門